Abbott Laboratories (ABT) — closed signal from October 28, 2025
Partial Published before the outcome was known, scored automatically when the window closed on January 26, 2026 — -14.5% at the close.
Predicted vs. what happened
What happened
Reached 32% of the predicted growth at its peak, without hitting the target.
The thesis — published October 28, 2025
Abbott looks like a steady, lower-risk stock that has fallen more than usual, which could offer a short-term opportunity. A major bank kept a $157 target, while another view says shares may be expensive, so balance optimism with care. Strong cash coming in and long-running dividends may help the price drift up over the next 3 months. Trend signs are still weak, so consider starting near the low end and add only if buyer interest improves.
Primary drivers
- The stock has dropped more than usual, yet the business is steady and resilient
- A major bank shows confidence and sets a $157 price goal, lifting sentiment
- Strong free cash and dependable dividends help support the share price
- Some think shares are pricey, so move carefully and keep positions modest
How it played out
ABT: the 12% target was not reached
Lyra published ABT on 2025-10-28 at $127.21 with an expected 12% short-term rise to $142.48. The thesis pointed to a steady business after a larger-than-usual drop, a major bank's $157 price goal, strong free cash, dependable dividends, and some caution that the shares may already be pricey.
Inside the window, ABT rose to $132.03 on 2025-11-18, a 3.8% peak gain. It stayed below the $142.48 target and never reached it. By 2026-01-26, the stock ended at $108.77. The thesis only partially played out: there was an early rise, but the target missed and the signal ended lower.
What happened during the window
On 2025-11-20, Abbott announced an agreement to acquire Exact Sciences. On 2026-01-22, Abbott reported fourth-quarter and full-year 2025 results and issued its 2026 financial outlook.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.